Oramed announces $36.9M investment and collaboration with Alpha Tau

Oramed (ORMP) has closed a strategic investment in Alpha Tau (DRTS). Through a registered direct offering, an affiliate of Oramed purchased approximately 14.1 million Alpha Tau’s ordinary shares, at a purchase price of $2.612 per share. As part of this collaboration, the parties have entered into a comprehensive three-year service agreement whereby Oramed will provide Alpha Tau with investor and shareholder outreach, business strategic guidance, and capital markets expertise. This strategic investment aligns with Oramed’s growth strategy to expand its footprint in innovative therapeutic delivery technologies, enabling Oramed to contribute to Alpha Tau’s strategic direction while supporting its market presence and accelerating its path to commercialization. Additionally, Oramed will take an active governance role with the appointment of two directors to Alpha Tau’s Board of Directors.